vs

Side-by-side financial comparison of Palladyne AI Corp. (PDYN) and Roivant Sciences Ltd. (ROIV). Click either name above to swap in a different company.

Roivant Sciences Ltd. is the larger business by last-quarter revenue ($2.0M vs $1.7M, roughly 1.2× Palladyne AI Corp.). Palladyne AI Corp. runs the higher net margin — -89.9% vs -13301.2%, a 13211.3% gap on every dollar of revenue. On growth, Palladyne AI Corp. posted the faster year-over-year revenue change (118.3% vs -77.8%). Palladyne AI Corp. produced more free cash flow last quarter ($-8.7M vs $-201.4M). Over the past eight quarters, Palladyne AI Corp.'s revenue compounded faster (-30.5% CAGR vs -73.7%).

Palladyne AI Corp. is an American company known for most of its existence primarily as a developer of robots. Palladyne was founded in 1983 as Sarcos Research Corporation. In 2023, Sarcos shifted its business focus to the development of artificial intelligence (AI) software for robotic applications, discontinuing its hardware operations. In March 2024, the company changed its name to Palladyne AI.

Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. It was founded in 2014 by Vivek Ramaswamy and is currently headed by CEO Matt Gline. Roivant maintains its headquarters in New York City as well as major offices in the biotech hubs of Boston and Basel.

PDYN vs ROIV — Head-to-Head

Bigger by revenue
ROIV
ROIV
1.2× larger
ROIV
$2.0M
$1.7M
PDYN
Growing faster (revenue YoY)
PDYN
PDYN
+196.1% gap
PDYN
118.3%
-77.8%
ROIV
Higher net margin
PDYN
PDYN
13211.3% more per $
PDYN
-89.9%
-13301.2%
ROIV
More free cash flow
PDYN
PDYN
$192.7M more FCF
PDYN
$-8.7M
$-201.4M
ROIV
Faster 2-yr revenue CAGR
PDYN
PDYN
Annualised
PDYN
-30.5%
-73.7%
ROIV

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
PDYN
PDYN
ROIV
ROIV
Revenue
$1.7M
$2.0M
Net Profit
$-1.5M
$-265.9M
Gross Margin
15.6%
Operating Margin
-560.7%
-16966.1%
Net Margin
-89.9%
-13301.2%
Revenue YoY
118.3%
-77.8%
Net Profit YoY
97.2%
-257.0%
EPS (diluted)
$-0.02
$-0.38

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PDYN
PDYN
ROIV
ROIV
Q4 25
$1.7M
$2.0M
Q3 25
$860.0K
$1.6M
Q2 25
$1.0M
$2.2M
Q1 25
$1.7M
$-39.6M
Q4 24
$761.0K
$9.0M
Q3 24
$871.0K
$4.5M
Q2 24
$2.7M
$8.0M
Q1 24
$3.4M
$28.9M
Net Profit
PDYN
PDYN
ROIV
ROIV
Q4 25
$-1.5M
$-265.9M
Q3 25
$-3.7M
$-113.5M
Q2 25
$-7.5M
$-223.4M
Q1 25
$22.8M
$-206.5M
Q4 24
$169.4M
Q3 24
$-7.1M
$-230.2M
Q2 24
$-5.3M
$95.3M
Q1 24
$-7.2M
$-151.1M
Gross Margin
PDYN
PDYN
ROIV
ROIV
Q4 25
15.6%
Q3 25
46.4%
Q2 25
53.3%
Q1 25
79.4%
Q4 24
27.2%
Q3 24
45.0%
Q2 24
79.0%
Q1 24
45.2%
Operating Margin
PDYN
PDYN
ROIV
ROIV
Q4 25
-560.7%
-16966.1%
Q3 25
-937.8%
-19492.9%
Q2 25
-797.4%
-13130.0%
Q1 25
-405.3%
674.8%
Q4 24
-3042.6%
Q3 24
-838.0%
-7636.0%
Q2 24
-213.3%
-1279.5%
Q1 24
-213.7%
-919.5%
Net Margin
PDYN
PDYN
ROIV
ROIV
Q4 25
-89.9%
-13301.2%
Q3 25
-434.9%
-7225.9%
Q2 25
-737.6%
-10292.9%
Q1 25
1330.9%
521.8%
Q4 24
1878.3%
Q3 24
-814.7%
-5143.8%
Q2 24
-196.2%
1192.7%
Q1 24
-210.1%
-522.3%
EPS (diluted)
PDYN
PDYN
ROIV
ROIV
Q4 25
$-0.02
$-0.38
Q3 25
$-0.09
$-0.17
Q2 25
$-0.20
$-0.33
Q1 25
$0.55
$-0.28
Q4 24
$0.23
Q3 24
$-0.27
$-0.31
Q2 24
$-0.20
$0.12
Q1 24
$-0.28
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PDYN
PDYN
ROIV
ROIV
Cash + ST InvestmentsLiquidity on hand
$47.1M
$4.5B
Total DebtLower is stronger
Stockholders' EquityBook value
$74.7M
$4.3B
Total Assets
$95.7M
$5.2B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PDYN
PDYN
ROIV
ROIV
Q4 25
$47.1M
$4.5B
Q3 25
$57.1M
$4.4B
Q2 25
$62.7M
$4.5B
Q1 25
$46.6M
$4.9B
Q4 24
$40.1M
$5.1B
Q3 24
$21.3M
$5.4B
Q2 24
$25.8M
$5.7B
Q1 24
$31.8M
$6.5B
Total Debt
PDYN
PDYN
ROIV
ROIV
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
$311.7M
Q1 24
$430.6M
Stockholders' Equity
PDYN
PDYN
ROIV
ROIV
Q4 25
$74.7M
$4.3B
Q3 25
$51.8M
$4.4B
Q2 25
$53.8M
$4.3B
Q1 25
$28.3M
$4.7B
Q4 24
$-9.5M
$5.2B
Q3 24
$23.4M
$5.2B
Q2 24
$29.8M
$5.4B
Q1 24
$34.2M
$6.0B
Total Assets
PDYN
PDYN
ROIV
ROIV
Q4 25
$95.7M
$5.2B
Q3 25
$72.9M
$5.1B
Q2 25
$78.3M
$5.0B
Q1 25
$63.3M
$5.4B
Q4 24
$56.3M
$5.8B
Q3 24
$38.7M
$6.2B
Q2 24
$45.1M
$6.5B
Q1 24
$50.4M
$7.2B
Debt / Equity
PDYN
PDYN
ROIV
ROIV
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
0.06×
Q1 24
0.07×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PDYN
PDYN
ROIV
ROIV
Operating Cash FlowLast quarter
$-8.5M
$-196.5M
Free Cash FlowOCF − Capex
$-8.7M
$-201.4M
FCF MarginFCF / Revenue
-526.2%
-10076.0%
Capex IntensityCapex / Revenue
14.2%
246.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-776.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PDYN
PDYN
ROIV
ROIV
Q4 25
$-8.5M
$-196.5M
Q3 25
$-6.3M
$-185.7M
Q2 25
$-5.3M
$-204.4M
Q1 25
$-7.5M
$-172.6M
Q4 24
$-22.6M
$-207.3M
Q3 24
$-4.5M
$-266.8M
Q2 24
$-5.8M
$-192.8M
Q1 24
$-7.2M
$-108.5M
Free Cash Flow
PDYN
PDYN
ROIV
ROIV
Q4 25
$-8.7M
$-201.4M
Q3 25
$-6.7M
$-193.5M
Q2 25
$-208.4M
Q1 25
$-7.6M
$-173.4M
Q4 24
$-22.9M
$-209.1M
Q3 24
$-4.5M
$-267.8M
Q2 24
$-5.9M
$-193.8M
Q1 24
$-7.3M
$-108.8M
FCF Margin
PDYN
PDYN
ROIV
ROIV
Q4 25
-526.2%
-10076.0%
Q3 25
-776.0%
-12317.8%
Q2 25
-9604.5%
Q1 25
-445.0%
438.1%
Q4 24
-3008.1%
-2318.5%
Q3 24
-517.8%
-5984.4%
Q2 24
-218.9%
-2425.5%
Q1 24
-212.1%
-376.1%
Capex Intensity
PDYN
PDYN
ROIV
ROIV
Q4 25
14.2%
246.9%
Q3 25
44.7%
499.6%
Q2 25
0.0%
185.9%
Q1 25
5.4%
-2.0%
Q4 24
34.8%
20.3%
Q3 24
1.4%
22.3%
Q2 24
5.3%
12.1%
Q1 24
1.8%
1.2%
Cash Conversion
PDYN
PDYN
ROIV
ROIV
Q4 25
Q3 25
Q2 25
Q1 25
-0.33×
Q4 24
-1.22×
Q3 24
Q2 24
-2.02×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons